Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives $24.15 Average Target Price from Analysts

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned an average recommendation of “Moderate Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $24.1538.

CMPS has been the topic of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a report on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Compass Pathways in a report on Wednesday, July 8th. BTIG Research boosted their price target on Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Compass Pathways in a research note on Tuesday, July 7th. Finally, Stifel Nicolaus raised their price objective on Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th.

Institutional Investors Weigh In On Compass Pathways

Several hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its holdings in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Compass Pathways in the fourth quarter valued at about $38,000. Parallel Advisors LLC lifted its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after buying an additional 7,183 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter worth about $41,000. Finally, North Star Investment Management Corp. boosted its holdings in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after buying an additional 7,000 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Price Performance

NASDAQ:CMPS opened at $11.93 on Friday. Compass Pathways has a 1-year low of $3.92 and a 1-year high of $15.40. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm has a fifty day simple moving average of $12.47 and a 200 day simple moving average of $8.96. The stock has a market capitalization of $1.61 billion, a PE ratio of -3.79 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, research analysts expect that Compass Pathways will post -1.24 EPS for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.